USA2 Spotlight 

Alzheimer's Talks: Next week you will have the opportunity to talk with an Alzheimer’s researcher about a brand-new study that is now recruiting participants. Dr. Laura Baker will share with us information on the EXERT Study: Building Memories through Exercise. EXERT will be conducted at YMCAs across the country to see whether physical exercise can slow memory loss and other symptoms of Alzheimer’s disease. We will also learn about the research that suggests why exercise might be beneficial for the brain. Click here to sign up for the Alzheimer’s Talks call on Wednesday, November 16, at 3 p.m. Eastern!

MUST READS

A November 10, 2016 Scientific American article reported that “Priorities at NIH, the BRAIN Initiative, drug price controls, and more initiatives could shift in major ways” under a Trump administration. According to the article, “So, too, is Gingrich, a friend of the drug industry who has also crusaded for broader research into Alzheimer’s and dementia. Also mentioned is Rich Bagger, a longtime biopharma exec who took a leave of absence from his role at biotech giant Celgene to serve as executive director of the Trump transition team under his friend New Jersey Governor Chris Christie.”

A November 9, 2016 Research Gate article rounded up reactions to the election of Donald Trump from the research community. According to Robert Egge, Chief Public Policy Officer of the Alzheimer's Association, “We are looking forward to working with his administration to end Alzheimer's, our nation’s most expensive disease. We are also hopeful, because so many of our leaders in Congress are excited to continue to work in a bipartisan way to advance public policies that will improve the lives of those living with Alzheimer's disease and their caregivers.”

A November 9, 2016 MIT News article reported that a “Study finds a complex series of molecular, cellular, circuit and network-level changes contribute to the progression of Alzheimer’s.” According to the article, “Now, in a review paper published in the journal Nature, researchers at the Picower Institute for Learning and Memory at MIT argue that while elevated amyloid-β levels may initiate the sequence of events that lead to the disease, a complex series of other molecular, cellular, circuit and network-level changes contribute to its progression. What’s more, the researchers argue, these changes cannot be reversed simply by controlling amyloid-β levels.”

A November 9, 2016 Science Daily article reported that “In a new study, researchers investigate the role of mitochondria in Alzheimer's disease pathology.”